Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells
Camille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, Marie Michelas, Carlos Martinez-Gomez, Carlos Gomez-Roca, Victor Sarradin, Marie Tosolini, Carine Valle, Frédéric Pont, Gwénaël Ferron, Laurence Gladieff, Sébastien Vergez, Agnès Dupret-Bories, Eliane Mery, Philippe Rochaix, Jean-Jacques Fournié, Jean-Pierre Delord, Christel Devaud, Alejandra Martinez, Maha Ayyoub
Camille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, Marie Michelas, Carlos Martinez-Gomez, Carlos Gomez-Roca, Victor Sarradin, Marie Tosolini, Carine Valle, Frédéric Pont, Gwénaël Ferron, Laurence Gladieff, Sébastien Vergez, Agnès Dupret-Bories, Eliane Mery, Philippe Rochaix, Jean-Jacques Fournié, Jean-Pierre Delord, Christel Devaud, Alejandra Martinez, Maha Ayyoub
View: Text | PDF
Research Article Immunology

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells

  • Text
  • PDF
Abstract

Tumor antigen–specific CD4 T cells accumulate at tumor sites, evoking their involvement in antitumor effector functions in situ. Contrary to CD8 cytotoxic T lymphocyte exhaustion, that of CD4 T cells remains poorly appreciated. Here, using phenotypic, transcriptomic, and functional approaches, we characterized CD4 T cell exhaustion in patients with head and neck, cervical, and ovarian cancer. We identified a CD4 tumor-infiltrating lymphocyte (TIL) population, defined by high PD-1 and CD39 expression, which contained high proportions of cytokine-producing cells, although the quantity of cytokines produced by these cells was low, evoking an exhausted state. Terminal exhaustion of CD4 TILs was instated regardless of TIM-3 expression, suggesting divergence with CD8 T cell exhaustion. scRNA-Seq and further phenotypic analyses uncovered similarities with the CD8 T cell exhaustion program. In particular, PD-1hiCD39+ CD4 TILs expressed the exhaustion transcription factor TOX and the chemokine CXCL13 and were tumor antigen specific. In vitro, PD-1 blockade enhanced CD4 TIL activation, as evidenced by increased CD154 expression and cytokine secretion, leading to improved dendritic cell maturation and consequently higher tumor-specific CD8 T cell proliferation. Our data identify exhausted CD4 TILs as players in responsiveness to immune checkpoint blockade.

Authors

Camille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, Marie Michelas, Carlos Martinez-Gomez, Carlos Gomez-Roca, Victor Sarradin, Marie Tosolini, Carine Valle, Frédéric Pont, Gwénaël Ferron, Laurence Gladieff, Sébastien Vergez, Agnès Dupret-Bories, Eliane Mery, Philippe Rochaix, Jean-Jacques Fournié, Jean-Pierre Delord, Christel Devaud, Alejandra Martinez, Maha Ayyoub

×

Figure 2

PD-1hiCD39+ tumor-infiltrating CD4 Tconvs are functionally exhausted.

Options: View larger image (or click on image) Download as PowerPoint
PD-1hiCD39+ tumor-infiltrating CD4 Tconvs are functionally exhausted.
(A...
(A and B) Isolated CD4+ TILs were stimulated in vitro with PMA/ionomycin and stained and analyzed by flow cytometry. (A) Top left dot plot shows PD-1 versus CD39 expression in CD4 Tconvs. IFN-γ versus TNF-α expression is shown in the indicated CD4 Tconv populations. Proportions of cytokine+ (IFN-γ and/or TNF-α; bottom left) and TNF-α+IFN-γ–, TNF-α–IFN-γ+, and TNF-α+IFN-γ+ cells in PD-1–CD39–, PD-1loCD39–, PD-1hiCD39–, and PD-1hiCD39+ subsets and according to TIM-3 expression (n = 8). (B) Dot plots show CD39 versus IFN-γ or TNF-α in CD4 Tconvs. Numbers in dot plots correspond to MFI of cytokine staining. MFI of IFN-γ and TNF-α staining in IFN-γ+ and TNF-α+ cells, respectively, are summarized for Tconv subpopulations defined as in A (n = 8). Samples in A and B are shown according to the proportion of TIM-3+ cells among PD-1hiCD39+ CD4 Tconv (<50% TIM-3+, square; ≥50% TIM-3+, triangle; unknown, round) (C) CD4 Tconv TIL subsets PD-1–CD39– (gray), PD-1loCD39– (green), PD-1hiCD39– (blue), and PD-1hiCD39+ (red) were sorted, expanded in vitro for 10 days, and restimulated or not with PMA/ionomycin overnight. TNF-α and IFN-γ secretion was quantified by CBA in the supernatant (n = 5). (D) Isolated CD4+ TILs were stained ex vivo and analyzed by flow cytometry. Proportions of TOX+ cells in each Tconv subset are summarized (n = 10). Data are presented as mean ± SD. **P < 0.01; ***P < 0.001; ****P < 0.0001. P values were determined using the Wilcoxon (A and B) and 2-tailed paired t tests (D). Bonferroni’s correction was applied to account for multiple testing in D and significance level was adjusted accordingly (*P < 0.0083; **P < 0.00166; ***P < 0.000166). Tconvs, conventional FOXP3- CD4 T cells; CBA, cytometric bead array; TILs, tumor-infiltrating lymphocytes.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts